AVIDITY BIOSCIENCES INC (RNA) Stock Fundamental Analysis
USA - NASDAQ:RNA - US05370A1088 - Common Stock
69.83 USD
+0.03 (+0.04%)
69.85 USD
+0.02 (+0.03%)
RNA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for RNA as it has an excellent financial health rating, but there are worries on the profitability. RNA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year RNA has reported negative net income.
RNA had a negative operating cash flow in the past year.
In the past 5 years RNA always reported negative net income.
In the past 5 years RNA always reported negative operating cash flow.
1.2 Ratios
RNA's Return On Assets of -33.29% is fine compared to the rest of the industry. RNA outperforms 63.86% of its industry peers.
The Return On Equity of RNA (-38.21%) is better than 72.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.29% | ||
| ROE | -38.21% | ||
| ROIC | N/A |
ROA(3y)-27.2%
ROA(5y)-24.5%
ROE(3y)-31.7%
ROE(5y)-28.1%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for RNA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
RNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
RNA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RNA has more shares outstanding
RNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
RNA has an Altman-Z score of 30.80. This indicates that RNA is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 30.80, RNA belongs to the top of the industry, outperforming 94.19% of the companies in the same industry.
RNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 30.8 |
ROIC/WACCN/A
WACC8.77%
2.3 Liquidity
A Current Ratio of 9.26 indicates that RNA has no problem at all paying its short term obligations.
RNA's Current ratio of 9.26 is fine compared to the rest of the industry. RNA outperforms 79.40% of its industry peers.
RNA has a Quick Ratio of 9.26. This indicates that RNA is financially healthy and has no problem in meeting its short term obligations.
RNA has a Quick ratio of 9.26. This is in the better half of the industry: RNA outperforms 79.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.26 | ||
| Quick Ratio | 9.26 |
3. Growth
3.1 Past
The earnings per share for RNA have decreased strongly by -21.09% in the last year.
The Revenue has been growing slightly by 1.21% in the past year.
The Revenue has been growing by 36.26% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-21.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-86.15%
Revenue 1Y (TTM)1.21%
Revenue growth 3Y5.31%
Revenue growth 5Y36.26%
Sales Q2Q%88.12%
3.2 Future
Based on estimates for the next years, RNA will show a very strong growth in Earnings Per Share. The EPS will grow by 23.95% on average per year.
RNA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 170.60% yearly.
EPS Next Y-55.33%
EPS Next 2Y-30.77%
EPS Next 3Y-4.49%
EPS Next 5Y23.95%
Revenue Next Year7.77%
Revenue Next 2Y49.81%
Revenue Next 3Y232.61%
Revenue Next 5Y170.6%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
RNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
RNA's earnings are expected to decrease with -4.49% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-30.77%
EPS Next 3Y-4.49%
5. Dividend
5.1 Amount
RNA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
69.83
+0.03 (+0.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners100.03%
Inst Owner Change-1.57%
Ins Owners0.83%
Ins Owner Change-0.14%
Market Cap9.48B
Revenue(TTM)10.73M
Net Income(TTM)-455743000
Analysts85.45
Price Target72.55 (3.9%)
Short Float %15.76%
Short Ratio7.43
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-10.42%
Min EPS beat(2)-21.39%
Max EPS beat(2)0.55%
EPS beat(4)2
Avg EPS beat(4)-2.84%
Min EPS beat(4)-21.39%
Max EPS beat(4)9.54%
EPS beat(8)4
Avg EPS beat(8)-0.44%
EPS beat(12)8
Avg EPS beat(12)3.6%
EPS beat(16)10
Avg EPS beat(16)1.14%
Revenue beat(2)1
Avg Revenue beat(2)70.43%
Min Revenue beat(2)-18.03%
Max Revenue beat(2)158.88%
Revenue beat(4)2
Avg Revenue beat(4)47.03%
Min Revenue beat(4)-45.8%
Max Revenue beat(4)158.88%
Revenue beat(8)4
Avg Revenue beat(8)21.36%
Revenue beat(12)8
Avg Revenue beat(12)17.32%
Revenue beat(16)10
Avg Revenue beat(16)11.95%
PT rev (1m)3.92%
PT rev (3m)9.14%
EPS NQ rev (1m)-0.01%
EPS NQ rev (3m)-10.21%
EPS NY rev (1m)0.05%
EPS NY rev (3m)-10.99%
Revenue NQ rev (1m)-7.86%
Revenue NQ rev (3m)20.89%
Revenue NY rev (1m)-2.92%
Revenue NY rev (3m)37.13%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 883.73 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 7.95 | ||
| P/tB | 7.95 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.56
EYN/A
EPS(NY)-4.94
Fwd EYN/A
FCF(TTM)-3.7
FCFYN/A
OCF(TTM)-3.61
OCFYN/A
SpS0.08
BVpS8.78
TBVpS8.78
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.29% | ||
| ROE | -38.21% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-27.2%
ROA(5y)-24.5%
ROE(3y)-31.7%
ROE(5y)-28.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 417.33% | ||
| Cap/Sales | 118.52% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 9.26 | ||
| Quick Ratio | 9.26 | ||
| Altman-Z | 30.8 |
F-Score1
WACC8.77%
ROIC/WACCN/A
Cap/Depr(3y)219.55%
Cap/Depr(5y)307.52%
Cap/Sales(3y)46.55%
Cap/Sales(5y)39.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-86.15%
EPS Next Y-55.33%
EPS Next 2Y-30.77%
EPS Next 3Y-4.49%
EPS Next 5Y23.95%
Revenue 1Y (TTM)1.21%
Revenue growth 3Y5.31%
Revenue growth 5Y36.26%
Sales Q2Q%88.12%
Revenue Next Year7.77%
Revenue Next 2Y49.81%
Revenue Next 3Y232.61%
Revenue Next 5Y170.6%
EBIT growth 1Y-82.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-87.83%
EBIT Next 3Y-1.52%
EBIT Next 5YN/A
FCF growth 1Y-190.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-188.36%
OCF growth 3YN/A
OCF growth 5YN/A
AVIDITY BIOSCIENCES INC / RNA FAQ
Can you provide the ChartMill fundamental rating for AVIDITY BIOSCIENCES INC?
ChartMill assigns a fundamental rating of 4 / 10 to RNA.
Can you provide the valuation status for AVIDITY BIOSCIENCES INC?
ChartMill assigns a valuation rating of 0 / 10 to AVIDITY BIOSCIENCES INC (RNA). This can be considered as Overvalued.
Can you provide the profitability details for AVIDITY BIOSCIENCES INC?
AVIDITY BIOSCIENCES INC (RNA) has a profitability rating of 1 / 10.
What is the earnings growth outlook for AVIDITY BIOSCIENCES INC?
The Earnings per Share (EPS) of AVIDITY BIOSCIENCES INC (RNA) is expected to decline by -55.33% in the next year.